Pharmagreen Biotech Inc. (PHBI) intrinsic value & 10-year financials
Pharmagreen Biotech Inc. (PHBI) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 18, 2026)
- $0.20
- Market cap
- $43.7M
- Revenue (FY2022)
- —
- ROIC (10-yr avg)
- 46.3%
- Free cash flow (FY2022)
- —
PHBI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2022 | — | -$875.5K | — | — | — | 62.7% |
| FY2021 | — | -$4.5M | — | — | — | 25.9% |
| FY2020 | — | -$2.4M | — | — | — | 16.9% |
| FY2019 | — | -$767.5K | — | -$514.0K | — | 69.1% |
| FY2018 | — | -$1.1M | — | -$1.0M | — | 56.7% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Pharmagreen Biotech Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Pharmagreen Biotech Inc. has earned high returns on invested capital, averaging 46.3% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Pharmagreen Biotech Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Pharmagreen Biotech Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.